2025 catalysts: New I&I indications take center stage
Inflammation and immunology readouts to define new priority indications, modality opportunities in immune reset
Enthusiasm for inflammation and immunology drug development shows no signs of fading in 2025, as coming clinical catalysts define the next set of indications to benefit from the surge in I&I investment and research. This year’s milestones should also help determine the therapeutic modalities best suited to transforming the treatment paradigm in B cell-driven autoimmune diseases — replacing regular maintenance therapy with long-term remission, or even cure.
Inflammatory diseases affecting the skin, including psoriasis and atopic dermatitis, became major drivers of the surge in I&I activity in recent years, and while dermatological conditions remain a focus among this year’s clinical catalysts, other I&I aperture is broadening to new indications...